{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:18:11Z","timestamp":1760782691079,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,2,1]],"date-time":"2005-02-01T00:00:00Z","timestamp":1107216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2005,2]]},"DOI":"10.1016\/j.jaad.2004.05.044","type":"journal-article","created":{"date-parts":[[2005,1,26]],"date-time":"2005-01-26T07:18:55Z","timestamp":1106723935000},"page":"S17-S19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"S","title":["Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis"],"prefix":"10.1016","volume":"52","author":[{"given":"Uma","family":"Nadiminti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack L.","family":"Arbiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2004.05.044_bib1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","article-title":"Dermatomyositis","volume":"355","author":"Callen","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.05.044_bib2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.05.044_bib3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(00)04587-6","article-title":"Cancer types in dermatomyositis and polymyositis","volume":"357","author":"Maddison","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.05.044_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/lv.2000.6352","article-title":"Skin cancer in liver transplant recipients","volume":"6","author":"Otley","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jaad.2004.05.044_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1085-5629(03)00044-0","article-title":"Management of squamous cell carcinoma in organ transplant recipients","volume":"22","author":"Carucci","year":"2003","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jaad.2004.05.044_bib6","first-page":"532","article-title":"Cutaneous neoplasms in renal transplant recipients","volume":"12","author":"Rubel","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2004.05.044_bib7","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Medical progress\u2014skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2004.05.044_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0140-6736(89)90616-8","article-title":"Immunosuppressive properties of Fk-506 and rapamycin","volume":"2","author":"Thomson","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.05.044_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/eji.1830250239","article-title":"FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells","volume":"25","author":"Fruman","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaad.2004.05.044_bib10","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1074\/jbc.275.10.7416","article-title":"FKBP12-Rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions","volume":"275","author":"Peterson","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2004.05.044_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.immunol.14.1.483","article-title":"Immunopharmacology of rapamycin","volume":"14","author":"Abraham","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2004.05.044_bib12","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(00)05068-6","article-title":"Advances in transplantation tolerance","volume":"357","author":"Yu","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2004.05.044_bib13","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2004.05.044_bib14","first-page":"1541","article-title":"Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics","volume":"60","author":"Zhong","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2004.05.044_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2004.05.044_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.8-suppl_3-5","article-title":"Signal events: cell signal transduction and its inhibition in cancer","volume":"8","author":"Rowinsky","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2004.05.044_bib17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1432-2277.2003.tb00287.x","article-title":"Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment","volume":"16","author":"Garcia","year":"2003","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaad.2004.05.044_bib18","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1016\/S0041-1345(02)03511-X","article-title":"Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases","volume":"34","author":"Garcia","year":"2002","journal-title":"Transplant Proc"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204016548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962204016548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:35:22Z","timestamp":1759268122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962204016548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S0190962204016548"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2004.05.044","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2005,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2004.05.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}